MelCancerVac (ENOB-DB-01) / Lunai Bioworks - LARVOL DELTA

Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies. (PubMed, Commun Med (Lond)) - "Here, we applied the next generation phage display mimotope variation analysis (MVA) to profile antibody response and dissect the role of humoral immunity in targeted cancer therapies, namely anti-tumor dendritic cell vaccine (MelCancerVac) and immunotherapy with anti-PD-1 monoclonal antibodies (pembrolizumab). The antibody epitopes as biomarkers reflect melanoma-associated features of immune response, and also provide insights into the molecular pathways contributing to the pathogenesis of cancer. Concluding, antibody epitope response can be useful in predicting anti-cancer immunity elicited by immunotherapy."

Biomarker • IO biomarker • Journal • Immune Modulation • Immunology • Inflammation • Lung Cancer • Melanoma • Oncology • Solid Tumor